Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 4/20 | 0.42 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.42 |
| ▸ | ERBB3 | P21860 | 4/20 | 0.42 |
| ▸ | ERBB4 | Q15303 | 4/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | PGK1 | P00558 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | CSF1R | P07333 | 1/20 | 0.38 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.38 |
| ▸ | IGF1R | P08069 | 1/20 | 0.38 |
| ▸ | CTSC | P53634 | 1/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9939018 | 0.84 | CSF1R (0.39) | EGFRERBB2ERBB3ERBB4SYK | |
| SCHEMBL25895044 | 0.83 | SYK (0.41) | EGFRERBB2ERBB3ERBB4SYK | |
| SCHEMBL9939040 | 0.82 | SYK (0.40) | EGFRERBB2ERBB3ERBB4SYK | |
| SCHEMBL22163140 | 0.82 | EGFR (0.39) | EGFRERBB2ERBB3ERBB4SYK | |
| SCHEMBL22163228 | 0.80 | EGFR (0.38) | EGFRERBB2ERBB3ERBB4SYK | |
| SCHEMBL9943691 | 0.80 | BRD4 (0.40) | EGFRERBB2ERBB3ERBB4SYK | |
| SCHEMBL22135118 | 0.75 | EGFR (0.39) | EGFRERBB2KMT2AMEN1NPC1 | |
| SCHEMBL23624476 | 0.74 | TNF (0.48) | EGFRERBB2ERBB3ERBB4SYK | |
| SCHEMBL20124506 | 0.74 | ABCG2 (0.37) | SYKKMT2AMEN1NPC1RAB9A | |
| SCHEMBL22135123 | 0.71 | SYK (0.35) | EGFRERBB2ERBB3ERBB4SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023139233-A1 | COMBINATION OF 8-CHLORO-N-(4-(TRIFLUOROMETHOXY)PHENYL)QUINOLIN-2-AMINE AND ITS DERIVATIVES WITH A JAK INHIBITOR | ABIVAX (FR) | 2023-07-27 | — | — | WO | disclosed |
| EP-4215196-A1 | COMBINATION OF 8-CHLORO-N-(4-(TRIFLUOROMETHOXY)PHENYL)QUINOLIN-2-AMINE AND ITS DERIVATIVES WITH A JAK INHIBITOR | ABIVAX (FR) | 2023-07-26 | — | — | EP | disclosed |
| WO-2023135207-A1 | COMBINATION OF 8-CHLORO-N-(4-(TRIFLUOROMETHOXY)PHENYL)QUINOLIN-2-AMINE AND ITS DERIVATIVES WITH A S1P RECEPTOR MODULATOR | ABIVAX (FR) | 2023-07-20 | — | — | WO | disclosed |
| EP-4212156-A1 | COMBINATION OF 8-CHLORO-N-(4-(TRIFLUOROMETHOXY)PHENYL)QUINOLIN-2-AMINE AND ITS DERIVATIVES WITH A S1P RECEPTOR MODULATOR | ABIVAX (FR) | 2023-07-19 | — | — | EP | disclosed |
| US-20220145406-A1 | BIOMARKERS, AND USES IN TREATMENT OF VIRAL INFECTIONS, INFLAMMATIONS, OR CANCER | ABIVAX (FR) | 2022-05-12 | — | — | US | disclosed |
| US-20220023324-A1 | QUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OF INFLAMMATION DISEASES | ABIVAX (FR) | 2022-01-27 | — | — | US | disclosed |
| WO-2020127853-A1 | BIOMARKERS, AND USES IN TREATMENT OF VIRAL INFECTIONS, INFLAMMATIONS, OR CANCER | ABIVAX (FR) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020127843-A1 | QUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OF INFLAMMATION DISEASES | ABIVAX (FR) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020127839-A1 | QUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OR PREVENTION OF CANCER | ABIVAX (FR) | 2020-06-25 | — | — | WO | disclosed |
| EP-3669873-A1 | QUINOLINE DERIVATIVES FOR USE INE THE TRAEATMENT OF INFLAMMATION DISEASES | ABIVAX (FR) | 2020-06-24 | — | — | EP | disclosed |
| EP-3670659-A1 | BIOMARKERS, AND USES IN TREATMENT OF VIRAL INFECTIONS, INFLAMMATIONS, OR CANCER | ABIVAX (FR) | 2020-06-24 | — | — | EP | disclosed |
| EP-3669874-A1 | QUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OR PREVENTION OF CANCER | ABIVAX (FR) | 2020-06-24 | — | — | EP | disclosed |
| US-9061999-B2 | Compounds useful for treating AIDS | ABIVAX (FR) | 2015-06-23 | — | — | US | disclosed |
| US-9061999-B2 | Compounds useful for treating AIDS | ABIVAX (FR) | 2015-06-23 | — | — | US | disclosed |
| US-20130267703-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | SPLICOS (FR) | 2013-10-10 | — | — | US | disclosed |
| US-20130267703-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | SPLICOS (FR) | 2013-10-10 | — | — | US | disclosed |
| EP-2465502-A1 | Compounds useful for treating AIDS | Société Splicos (FR) | 2012-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267703-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | CBR3, CBR1, CCR10 | EGFR 2519/4885ERBB2 4270/4885ERBB3 1663/4885 |
| US-20220023324-A1 | QUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OF INFLAMMATION DISEASES | NR1H3, NR1H2, NR1H4 | EGFR 2316/4885ERBB2 1953/4885ERBB3 2035/4885 |
| US-20220145406-A1 | BIOMARKERS, AND USES IN TREATMENT OF VIRAL INFECTIONS, INFLAMMATIONS, OR CANCER | HAVCR2, CXCL8, IL36G | EGFR 686/4885ERBB2 1603/4885ERBB3 1723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.